IDEAYA Biosciences Reveals Promising IDE849 Data for SCLC

Author: Dylan Bailey Updated: 09-07-2025 12:09 PM

IDEAYA Biosciences Shows Strong Results for IDE849 in SCLC Trials

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) and Hengrui Pharma have unveiled impressive Phase 1 clinical trial data concerning IDE849 (SHR-4849), a promising candidate for treating small cell lung cancer (SCLC). At a recent oncology conference, the results highlighted a robust overall response rate (ORR) across diverse treatment cohorts.

Key Efficacy Findings

The study revealed a compelling ORR of 80.0% in patients receiving the 2.4 mg/kg dosage for second-line SCLC treatment. The findings suggest that IDE849 holds significant potential, with a confirmed ORR of 70.0% in this subset of patients. Furthermore, the study demonstrated a 73.7% ORR among all SCLC patients at the same dosage.

Noteworthy Observations in Advanced Cases

In cases involving patients with brain metastases, a confirmed ORR of 83.3% was achieved at the 2.4 mg/kg dose. Across various dosing levels, the data indicated that IDE849 could consistently demonstrate effectiveness, especially in patients who had already undergone multiple lines of prior therapy.

Median Progression-Free Survival Rates

The clinical trial also tracked the median progression-free survival (PFS), reporting an encouraging 6.7 months across all lines of treatment at doses ?2.4 mg/kg. Notably, the median PFS had not yet been reached in the second-line treatment cohort.

Safety Profile of IDE849

The safety profile of IDE849 appeared manageable, even across various dosing regimens. From a total of 100 patients treated, 48% experienced grade 3 or higher treatment-related adverse events, with neutropenia being the most frequently recorded issue. Importantly, the treatment-related discontinuation rate remained low at 2% with no treatment-related fatalities observed.

Implications for Future Development

The data showcased at the conference signals IDEAYA's commitment to advancing IDE849’s development not only in SCLC but also in neuroendocrine tumors (NETs) and other solid tumors with heightened DLL3 expression. This expansive vision anticipates meeting significant unmet needs in cancer therapy.

Company Overview

IDEAYA Biosciences stands at the forefront of precision medicine in oncology. Focused on uncovering transformative cancer therapies, the company integrates advanced methodologies in drug discovery and bioinformatics. With a deep pipeline catering to various cancer types, IDEAYA aims to create targeted treatments aligned with genetic disease drivers.

Frequently Asked Questions

What is IDE849?

IDE849 (SHR-4849) is a novel antibody-drug conjugate targeting DLL3 and designed to treat small cell lung cancer.

What were the response rates observed in the trial?

The trial showed an 80.0% ORR at the 2.4 mg/kg dose for patients in the second-line treatment setting.

What were the safety findings of the study?

The study found a manageable safety profile with 48% of patients experiencing grade 3 or higher treatment-related adverse events.

How long was the median progression-free survival?

The median PFS reported was 6.7 months across all lines of treatment at doses of IDE849 ?2.4 mg/kg.

What is IDEAYA's mission?

IDEAYA's mission is to pioneer precision oncology therapies that improve outcomes for cancer patients through targeted treatments aligned with the genetic drivers of disease.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.